share_log

东诚药业:下属公司在研产品177Lu-LNC1004获得FDA快速通道资格

yantai dongcheng biochemicals: Its subsidiary company's investigational product 177Lu-LNC1004 has obtained FDA fast track qualification.

Breakings ·  Oct 29 19:12

yantai dongcheng biochemicals announcement, its subsidiary company LNC PHARMA's application for 177Lu-LNC1004 injection has been granted fast track qualification by the FDA for the treatment of patients with advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer who have received at least one prior tyrosine kinase inhibitor therapy.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment